Comparison of original and biosimilar infliximab (CTP-13) in biologic-naïve patients with Crohn’s disease and ulcerative colitisa retrospective, multicenter real-life study in Spain

  1. Helena Martínez Lozano 1
  2. J. Miranda Bautista 1
  3. Yago González Lama 2
  4. Daniel Carpio López 3
  5. Manuel Barreiro de Acosta
  6. José Lázaro Pérez Calle
  7. Lucía Relea Pérez 2
  8. Keyla Villa 2
  9. Virginia Matallana 2
  10. Marta Calvo 2
  11. María Isabel Vera Mendoza 2
  12. Pablo Pérez Galindo 3
  13. Natalia Mora Cuadrado 4
  14. Pilar López Serrano 5
  15. Ignacio Marín Jiménez 1
  16. Luis Alberto Menchén 1
  1. 1 Hospital General Universitario Gregorio Marañón. Madrid, Spain
  2. 2 Hospital Universitario Puerta de Hierro. Madrid, Spain
  3. 3 Complejo Hospitalario Universitario de Pontevedra. Pontevedra, Spain.
  4. 4 Complejo Hospitalario Universitario de Santiago. Santiago de Compostela, Spain
  5. 5 Hospital Universitario Fundación de Alcorcón. Alcorcón, Madrid. Spain
Revista:
Revista Española de Enfermedades Digestivas

ISSN: 2340-416 1130-0108

Any de publicació: 2021

Volum: 113

Número: 3

Pàgines: 170-178

Tipus: Article

DOI: 10.17235/REED.2020.6847/2019 DIALNET GOOGLE SCHOLAR

Altres publicacions en: Revista Española de Enfermedades Digestivas

Resum

Purpose: biosimilar infliximab (CTP-13) has been recently approved for the treatment of several immune-mediated inflammatory disorders, including inflammatory bowel disease (IBD). Comparative studies between this biosimilar and original infliximab in the real clinical practice are scarce. The objective of this study was to compare short and long-term safety and efficacy of original (O) and biosimilar infliximab (B-IFX) in biologic-naïve, IBD patients in the real life clinical practice. Methods: a retrospective, multicentric study was performed in five Spanish hospitals. Consecutive IBD, biologic-naïve patients from an historic cohort who initiated O-IFX from January 2013 were compared with biologic-naïve patients, who started treatment with B-IFX since its approval in January 2015. The evaluation of efficacy was assessed after the induction phase, at week 14 and week 54 of treatment. Time to dose escalation or treatment persistence of both O-IFX and B-IFX was also considered. The appearance of serious adverse events was recorded. Results: two hundred and thirty-nine IBD biologic-naïve patients who started with O-IFX or B-IFX were included: 153 patients were diagnosed with Crohn’s disease (95 treated with O- and 58 treated with B-IFX) and 86 with ulcerative colitis (40 received O- and 46 received B-IFX). At weeks 14 and 54, both O-IFX and B-IFX groups reached a similar clinical response and remission rates. Time to dose escalation, treatment persistence and safety profile were comparable between both groups. Conclusions: this long-term real-life experience provides additional evidence of the similarity of O- and B-IFX CTP-13 in terms of efficacy and safety in IBD patients.